Jobs / United States / Glaxosmithkline LLC
Director, Integrative Sciences
Glaxosmithkline LLC · 🇺🇸 3 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles4 certified filings for “Associate Director – Genomic Technologies” (Molecular and Cellular Biologists) in PA: $134k–$138k, median $136k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
We create a place where people can grow, be their best, be safe, and feel welcome, valued and included. We offer a competitive salary, an annual bonus based on company performance, healthcare and wellbeing programmes, pension plan membership, and shares and savings programme. We embrace modern work practises; our Performance with Choice programme offers a hybrid working model, empowering you to find the optimal balance between remote and in-office work. Discover more about our company wide benefits and life at GSK on our webpage Life at GSK | GSK Director, Integrative Sciences We are seeking a visionary leader to join our Oncology Translational Medicine Integrative Sciences team as the Director of Integrative Sciences. This role will focus on driving innovation in diagnostic technology platforms, leveraging cutting-edge approaches such as oncology foundational models, real world data, multi-modal omics data, AI/ML, computational pathology, and biomarker discovery to transform how we understand and treat cancer. The successful candidate will play a pivotal role in shaping biomarker, diagnostic, and clinical development strategies, particularly in the context of antibody-drug conjugates (ADCs), T cell engagers and other advanced therapeutic modalities, while maintaining responsibilities for analyzing clinical trial biomarker data to enable translational medicine approaches. For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK Ware in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029 . Key Responsibilities In this role you will • Lead innovation in emerging diagnostic technologies, including ctDNA, computational pathology, advanced imaging techniques, and multi-modal biomarker platforms, to enhance patient stratification, therapeutic targeting, and mechanism-of-action insights. • Develop and apply oncology foundational models and AI/ML analytical approaches to complex clinical, real-world and biomarker datasets, including high-dimensional data such as single-cell transcriptomics, spatial omics, proteomics, and cfDNA. • Serve as a subject matter expert in application of analytical methods and emerging diagnostic technologies to enable biomarker discovery and diagnostic strategies to optimize patient selection, dose determination, and combination therapy approaches with a focus on antibody-drug conjugates (ADCs). • Oversee the integration of oncology foundational models to inform translational medicine and clinical development strategies ensuring robust interpretation, practical implementation and timely communication across matrix teams. • Collaborate with cross-functional teams, clinical development, CPMS (Clinical Pharmacology and Modelling Simulation), Diagnostic, Translational Research, and AI/ML teams, to evaluate and apply complementary data analytics approaches for meaningful insights into complex biology. • Lead efforts to identify, evaluate, and implement emerging technology platforms to advance diagnostic innovation and support pipeline growth. • Provide leadership and accountability for clear and timely communication of data analysis outputs, complex analytical principles, and models to diverse stakeholders, including senior leaders and non-technical partners. • Champion the integration of biomarker and diagnostic strategies into clinical development plans, ensuring alignment with oncology research unit and translational medicine objectives • Drive the application of computational pathology and AI-driven image analysis to enhance diagnosti